Loading...
Loading...
HOWL| Name | Value |
|---|---|
| Revenues | 7.3M |
| Cost of Revenue | 0.0M |
| Gross Profit | 7.3M |
| Operating Expense | 20.5M |
| Operating I/L | -13.2M |
| Other Income/Expense | 1.2M |
| Interest Income | 1.2M |
| Pretax | -11.9M |
| Income Tax Expense | -1.2M |
| Net Income/Loss | -10.7M |
Werewolf Therapeutics, Inc. is a biopharmaceutical company specializing in developing therapeutics that harness the body's immune system to treat cancer. The company's proprietary PREDATOR platform enables the design of conditionally activated molecules, such as WTX-124 and WTX-330, which stimulate adaptive and innate immunity to address the limitations of traditional proinflammatory immune therapies. These lead product candidates target advanced solid tumors, relapsed or refractory advanced or metastatic solid tumors, and lymphoma. Additionally, the company is developing WTX-613 for the treatment of solid tumors and hematologic malignancies.
